Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: Case study and review of data from the FDA adverse event reporting system

Neuro-Oncology

Volumn 14, Issue 5, 2012, Pages 541-546

  Sarganas, Giselle ^a   Orzechowski, Hans D ^a   Klimpel, Andreas ^a   Thomae, Michael ^b   Kauffmann, Wolfgang ^c   Herbst, Hermann ^d   Bronder, Elisabeth ^a   Garbe, Edeltraut ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Abteilung Innere Medizin Gastroenterologie   (Germany)

^c Vivantes Klinikum Friedrichshain   (Germany)

^d VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^e LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

Author keywords

Cholestasis; Glioblastoma multiforme; Hepatotoxicity; Temozolomide

Indexed keywords

DEXAMETHASONE; PANTOPRAZOLE; PARACETAMOL; PREDNISOLONE; SILYMARIN; TEMOZOLOMIDE; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHOLESTATIC HEPATITIS; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; EYE EXAMINATION; FOLLOW UP; GAIT DISORDER; GASTRODUODENAL ULCER; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGY; HOMONYMOUS HEMIANOPIA; HUMAN; JAUNDICE; MALE; POSTOPERATIVE PAIN; SIDE EFFECT; TUMOR DIAGNOSIS; VISUAL IMPAIRMENT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHOLESTASIS; DACARBAZINE; DRUG-INDUCED LIVER INJURY; GLIOBLASTOMA; HEPATITIS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860353759     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos056     Document Type: Article

References (16)

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
2. Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res. 1999;5:309-317.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
5. FDA Temodar Prescribing Information. Available at http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/021029s021,022277 s005lbl.pdf. Accessed September 30, 2011.
6. Garbe E, Andersohn F, Bronder E, et al. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol. 2011;154:644-653.
7. Drug Commission of the German Medical Association. AkdÄ . 2011. Available http://www.akdae.de/Arzneimittelsicherheit/Bekanntgaben/Archiv/2011/ 20110408.html. Accessed April 8, 2011.
8. Chheda MG, Drappatz J, Greenberger NJ, et al. Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology. 2007;68:955-956.
9. de Paiva TF, Jr, de Barros e Silva MJ, Rinck JA, Jr, et al. Tuberculosis in a patient on temozolomide: a case report. J Neurooncol. 2009;92: 33-35.
10. Goldbecker A, Tryc AB, Raab P, et al. Hepatic encephalopathy after treatment with temozolomide. J Neurooncol. 2011;103:163-166.
11. Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med. 2007;356:1591-1592.
12. Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol. 2006;24:4412-4417.
13. Neyns B, Hoorens A, Stupp R. Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. Acta Neurol Belg. 2008;108:131-134.
14. Weiler M, Hartmann C, Wiewrodt D, et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010;77:670-676.
15. Thomson AB, Sauve MD, Kassam N, et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323-2330.
16. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6:673-684.